Therapeutic SiRNA Targeting the Cancer Cell Stemness Regulator PRDI-BF1 and RIZ Domain Zinc Finger Protein 14

Overview

Journal Proc Jpn Acad Ser B Phys Biol Sci

Specialties Biology
Science

Date 2022 Jul 31

PMID 35908955

Authors

Kohzoh Imai

Hiroaki Taniguchi

Affiliations

Soon will be listed here.

Abstract

PRDI-BF1 and RIZ (PR) domain zinc finger protein 14 (PRDM14), first reported in 2007 to be overexpressed in breast cancer, plays an important role in breast cancer proliferation. Subsequent studies reported that PRDM14 is expressed in embryonic stem cells, primordial germ cells, and various cancers. PRDM14 was reported to confer stemness properties to cancer cells. These properties induce cancer initiation, cancer progression, therapeutic resistance, distant metastasis, and recurrence in refractory tumors. Therefore, PRDM14 may be an ideal therapeutic target for various types of tumors. Silencing PRDM14 expression using PRDM14-specific siRNA delivered through an innovative intravenous drug delivery system reduced the size of inoculated tumors, incidence of distant metastases, and increased overall survival in nude mice without causing adverse effects. Therapeutic siRNA targeting PRDM14 is now being evaluated in a human phase I clinical trial for patients with refractory breast cancer, including triple-negative breast cancer.

References

Moriya C, Taniguchi H, Nagatoishi S, Igarashi H, Tsumoto K, Imai K . PRDM14 directly interacts with heat shock proteins HSP90α and glucose-regulated protein 78. Cancer Sci. 2017; 109(2):373-383. PMC: 5797828. DOI: 10.1111/cas.13458. View

Shimizu H, Hori Y, Kaname S, Yamada K, Nishiyama N, Matsumoto S . siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol. 2010; 21(4):622-33. PMC: 2844303. DOI: 10.1681/ASN.2009030295. View

Barrett L, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland E . Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell. 2012; 21(1):11-24. DOI: 10.1016/j.ccr.2011.11.025. View

Simko S, Voicu H, Carofino B, Justice M . Mouse Lymphoblastic Leukemias Induced by Aberrant Expression Demonstrate Widespread Copy Number Alterations Also Found in Human ALL. Cancers (Basel). 2013; 4(4):1050-1066. PMC: 3593237. DOI: 10.3390/cancers4041050. View

Nishikawa N, Toyota M, Suzuki H, Honma T, Fujikane T, Ohmura T . Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 2007; 67(20):9649-57. DOI: 10.1158/0008-5472.CAN-06-4111. View

Mzoughi S, Tan Y, Low D, Guccione E . The role of PRDMs in cancer: one family, two sides. Curr Opin Genet Dev. 2016; 36:83-91. DOI: 10.1016/j.gde.2016.03.009. View

Carofino B, Ayanga B, Tracey L, Brooke-Bisschop T, Justice M . PRDM14 promotes RAG-dependent Notch1 driver mutations in mouse T-ALL. Biol Open. 2016; 5(5):645-53. PMC: 4874358. DOI: 10.1242/bio.017699. View

Taniguchi H, Natori Y, Miyagi Y, Hayashi K, Nagamura F, Kataoka K . Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex. Int J Cancer. 2021; 149(3):646-656. DOI: 10.1002/ijc.33579. View

Dettman E, Simko S, Ayanga B, Carofino B, Margolin J, Morse 3rd H . Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors. Oncogene. 2011; 30(25):2859-73. PMC: 3121925. DOI: 10.1038/onc.2011.12. View

10.

Okashita N, Kumaki Y, Ebi K, Nishi M, Okamoto Y, Nakayama M . PRDM14 promotes active DNA demethylation through the ten-eleven translocation (TET)-mediated base excision repair pathway in embryonic stem cells. Development. 2013; 141(2):269-80. DOI: 10.1242/dev.099622. View

11.

Snellenberg S, Cillessen S, Van Criekinge W, Bosch L, Meijer C, Snijders P . Methylation-mediated repression of PRDM14 contributes to apoptosis evasion in HPV-positive cancers. Carcinogenesis. 2014; 35(11):2611-8. DOI: 10.1093/carcin/bgu197. View

12.

Quintana E, Shackleton M, Sabel M, Fullen D, Johnson T, Morrison S . Efficient tumour formation by single human melanoma cells. Nature. 2008; 456(7222):593-8. PMC: 2597380. DOI: 10.1038/nature07567. View

13.

Chia N, Chan Y, Feng B, Lu X, Orlov Y, Moreau D . A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature. 2010; 468(7321):316-20. DOI: 10.1038/nature09531. View

14.

Yamaji M, Seki Y, Kurimoto K, Yabuta Y, Yuasa M, Shigeta M . Critical function of Prdm14 for the establishment of the germ cell lineage in mice. Nat Genet. 2008; 40(8):1016-22. DOI: 10.1038/ng.186. View

15.

Yamato K, Egawa N, Endo S, Ui-Tei K, Yamada T, Saigo K . Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. Cancer Gene Ther. 2011; 18(8):587-97. DOI: 10.1038/cgt.2011.28. View

16.

Gell J, Zhao J, Chen D, Hunt T, Clark A . PRDM14 is expressed in germ cell tumors with constitutive overexpression altering human germline differentiation and proliferation. Stem Cell Res. 2018; 27:46-56. PMC: 5858915. DOI: 10.1016/j.scr.2017.12.016. View

17.

Zhang T, Meng L, Dong W, Shen H, Zhang S, Liu Q . High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker in resected non-small cell lung cancer. Med Oncol. 2013; 30(3):605. DOI: 10.1007/s12032-013-0605-9. View

18.

Cho W, Albuquerque R, Kleinman M, Tarallo V, Greco A, Nozaki M . Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A. 2009; 106(17):7137-42. PMC: 2678451. DOI: 10.1073/pnas.0812317106. View

19.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

20.

Pittella F, Cabral H, Maeda Y, Mi P, Watanabe S, Takemoto H . Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. J Control Release. 2014; 178:18-24. DOI: 10.1016/j.jconrel.2014.01.008. View